The multiple sclerosis drug Lemtrada (alemtuzumab) is under scrutiny from the European Medicines Agency (EMA), according to the drug regulator’s April 12, 2019 press release, “Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing”. From this April 14, 2019 Medscape article, “PRAC Restricts Use of Alemtuzumab for MS … [Read more...]